Rein Therapeutics Inc.
RNTX
$1.76
-$0.15-7.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.36% | -55.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.51% | -32.84% | |||
| Operating Income | 4.51% | 32.84% | |||
| Income Before Tax | -627.30% | 34.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -600.89% | 34.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -600.89% | 34.61% | |||
| EBIT | 4.51% | 32.84% | |||
| EBITDA | 4.51% | 32.81% | |||
| EPS Basic | -599.93% | 39.90% | |||
| Normalized Basic EPS | 5.63% | 39.90% | |||
| EPS Diluted | -599.93% | 39.90% | |||
| Normalized Diluted EPS | 5.63% | 39.90% | |||
| Average Basic Shares Outstanding | 0.14% | 8.80% | |||
| Average Diluted Shares Outstanding | 0.14% | 8.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||